RPCEC00000123招募中4 期
Effectiveness and safety of ior®EPOCIM in Chronic Kidney Disease patients in pre-dialysis.
CIMAB-Center of Molecular Immunology (CIM)0 个研究点目标入组 425 人开始时间: 2011年11月11日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 425
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized controlled trial. Masking: Open. Control group: Uncontrolled. Assignment: Single group. Purpose: Treatment
入排标准
- 年龄范围
- 18 years 至 o limit（—）
- 性别
- All
入选标准
- •1. Patients that fulfill the diagnostic criteria. 2. Patients that give a written consent 3. Patient with age over or equal to 18 years. 4. Patients of both sexes.
排除标准
- •1. Patients with known hypersensitivity to products derived from superior cells or hypersensitivity to human albumin. 2. Pregnant or breastfeeding patients. 3. Patients with other non-renal anemia. 4. Patients with Class III-IV Heart Failure, according to the New York Heart Association Classification. 5. Patients with oncologic disease diagnose.
研究者
相似试验
暂停
2 期
Effect and Safety of ior® EPOCIM in patients with Non-Hodking Lymphoma treated with anthracyclines.Patients with Non-Hodking LymphomaRPCEC00000096Center of Molecular Immunology88
已完成
4 期
Effectiveness and Safety of ior EPOCIM in patients with Chronic Renal Failure on dialysis methods.Chronic Renal Insufficiency.RPCEC00000082Center of Molecular Immunology(CIM)621
尚未招募
2 期
ior®EPOCIM in post-COVID-19 convalescent patients with cardiovascular, renal and/or respiratory disordersCardiovascular, renal and respiratory disorders in convalescent patients from SARS-CoV-2 infectionCOVID-19SARS-CoV2Coronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirus/complicationsRespiratory Tract InfectionsCardiovascular InfectionsKidney DiseasesRPCEC00000376Center of Molecular Immunology (CIM)135
已完成
3 期
Effectiveness and safety of ior EPOCIM in anemia in premature infant.Anemia of preterm newbornRPCEC00000088Center of Molecular Immunology(CIM)72
暂停
3 期
EPOCIM in benign prostatic hyperplasia.Benign prostatic hyperplasiaRPCEC00000092Center of Molecular Immunology(CIM)306